Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking 

Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context

Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit 

Cervical cancer is a preventable disease so, although research advances are increasing treatment opportunities for all women diagnosed at any stage, we must stop it before it hits.

Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors 

Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone 

A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy 

Different methods – multiparametric biomarker assessment and FDG-PET – show mixed accuracy and their applicability in clinical practice needs to be assessed 

Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC